Mesoblast (MSB) H1 2026 earnings summary

Executive summary

• Achieved strong growth in Ryoncil/RYONCIL sales following FDA approval and U.S. launch in April 2025, with net revenue of $49 million and total revenue of $51.3 million in H1 FY2026, onboarding 49 treatment centers and securing coverage for 280 million U.S. lives.

• Strategic focus on label expansion, new indications, and advancing second-generation products, including Revascor and rexlemestrocel-L, while optimizing manufacturing and capital structure.

• Net loss narrowed to $40.2 million, a 16% improvement year-over-year, reflecting higher revenues and increased R&D and SG&A expenses.

• Cash reserves stood at $130 million at December 31, 2025, supported by a new $125 million credit facility.

• Continued investment in late-stage clinical programs and commercial expansion, with broad payer coverage and rapid onboarding of transplant centers.

Financial highlights

• Total revenues for H1 FY2026 were $51.3 million, with product sales of $48.7 million and royalty revenue of $2.7 million.

• Gross margin reached 93% for the period.

• R&D expenses rose to $46.2 million, mainly due to clinical advancement and platform technology investments.

• SG&A expenses increased to $28.5 million, reflecting commercialization activities.

• Net operating cash spend was $30.3 million; period-end cash balance was $130 million.

Outlook and guidance

• Full-year FY2026 Ryoncil/RYONCIL net revenue is projected between $110 million and $120 million.

• Operating cash flow usage/net cash spend expected to decline in H2 FY2026 due to increased revenues and cost controls.

• Expansion of Ryoncil/RYONCIL indications and further regulatory filings are planned, with continued investment in pipeline candidates.

• BLA filing for full approval of Revascor in end-stage HFrEF anticipated next quarter; CLBP Phase 3 trial enrollment to complete by March/April, with data readout and BLA filing targeted for 2027.

• Targeting 20% pediatric market share by fiscal year-end, with a long-term goal of 40% peak share.